.svg)
.svg)
.svg)
.svg)
Discover, develop and commercialise Artificial Amino Acid based medicines and diagnostics to treat patients with autoimmune and genetic diseases with the greatest unmet medical needs where current therapies are inadequate.
Contact Us
The A3SMO® Platform - the breakthrough molecular solution for the custom design of self-assembling artificial amino acid-based small molecules. It increases the drug-likeness of the molecules and creates first-in-class medicines to treat patients with major unmet clinical needs.
.png)
.png)
.svg)
%201.svg)
Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.
Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.
Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.
Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.
Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.
Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.
.svg)
The development of artificial amino acid-based pharmaceutics is a hot topic in the pharmaceutical industry and in basic research.
AzEpi-Pharma Gyógyszerkutató Korlátolt Felelősségű Társasága „Proteomimetikus peptid gyógyszerek fejlesztése és gyártása nagyáteresztő képességű innovatív platformon” címmel 114,34millió forint vissza nem térítendő támogatást nyert a Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal által meghirdetett „2020-1.1.5-GÍORSÍTÓSÁV” kódszámú, „GYORSÍTÓSÁV” felhívásán.
CalciMedica and EpiPharma today announced that they have entered into a collaboration agreement to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform
.svg)
